 |
24 March 2023
Neil Clark of Destiny Pharma discusses XF-73’s significant Phase 2 data published in a peer reviewed journal & potential upside. – Vox Markets |
|
 |
6 March 2023
Neil Clark updates Proactive Investors on progress |
|
 |
24 February 2023
Neil Clark & Shaun Claydon of Destiny Pharma: Collaboration for NTCD-M3 worth up to $570m plus royalties – Vox Markets |
|
 |
23 November 2022
Neil Clark speaks to Labiotech about Antimicrobial Resistance |
|
 |
18th November 2022
Bill Love speaks to Proactive Investors on addressing the Global Threat of superbugs and AMR |
|
 |
5th October 2022
Neil Clark speaks to StockBox Media on NTCD-M3 |
|
 |
8 September 2022
Neil Clark & Shaun Claydon of Destiny Pharma: Significant progress in H1 will continue in 2022 & beyond – Vox Markets |
|
 |
19 July 2022
Destiny Pharma discusses positive update from FDA on their XF-73 nasal gel |
|
 |
19 July 2022
Destiny Pharma to trial nasal gel in breast surgery after ‘positive’ FDA feedback |
|
 |
12 May 2022
Destiny Pharma plc on its two lead infection prevention assets |
|
 |
12 May 2022
Destiny Pharma highlights new ‘landmark’ NTCD-M3 data |
|
 |
April 2022
Destiny Pharma discusses 2021 highlights and what is expected in 2022 |
|
|
March 2022
Destiny Pharma presentation at the Proactive One2One Virtual Forum |
|
 |
March 2022
Destiny Pharma podcast presentation to Vox Markets ‘New funds will progress two lead clinical assets towards Phase 3 trials’ |
|
 |
February 2022
Destiny Pharma prepares to move to final study on novel XF-73 dermal formulation |
|
 |
December 2021
Destiny Pharma ‘2021 and beyond’ presentation to Vox Markets |
|
 |
December 2021
Destiny Pharma presentation at the Proactive One2One Investor Forum |
|
 |
November 2021
Professor Dale Gerding, a world leader in C. difficile infections speaks to Equity Development about the significant problem of CDI and how Destiny Pharma’s novel NTCD-M3 clinical programme can provide a breakthrough in patients’ treatment |
|
 |
November 2021
Destiny Pharma presentation on NTCD-M3 to the 9th Annual International C. diff Conference & Health Expo |
|
 |
October 2021
Alan Green talks to CEO Neil Clark |
|
 |
September 2021
Destiny Pharma presentation at the Proactive One2One Virtual Forum |
|
 |
August 2021
Destiny Pharma publish more evidence of surgery nasal gel effectiveness |
|
 |
July 2021
@VoiceAmericaTRN C. diff Spores and More radio programme – recorded 20th July at 1800 BST |
|
 |
July 2021
Destiny Pharma presentation at the Shares Investor Evening – 6th July 2021 |
|
 |
June 2021
Destiny Pharma presentation at the Cenkos Growth and Innovation Forum – 8th June 2021 |
|
 |
June 2021
Destiny Pharma consultant Professor Dale Gerding updates on recurrent C. difficile infections work |
|
 |
April 2021
Proactive Results Interview |
|
 |
April 2021
Developing Novel Medicines that Prevent Serious Infections |
|
 |
March 2021
Proactive Elevator Pitch |
